Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemo + SBRT in LAPC
NCT03600623Phase 1Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Sep 2017
- Primary completion
- Jul 2020
- Countries
- 1
01
Overview
Phase 1, open-label trial (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Number of participants with adverse events as a measure of safety and tolerability. Started Sep 2017; status: terminated.
Beyond the preview
Go deeper on NCT03600623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600623.